Programmed cell death 1‐expressing CD56‐negative natural killer (NK) cell expansion is a hallmark of chronic NK cell activation during dasatinib treatment-Reference-Cited by-同舟云学术

Programmed cell death 1‐expressing CD56‐negative natural killer (NK) cell expansion is a hallmark of chronic NK cell activation during dasatinib treatment

Published:2020-12-16 Issue:2 Volume:112 Page:523-536
ISSN:1347-9032
Container-title:Cancer Science
language:en
Short-container-title:Cancer Sci

Author:

Ishiyama Ken‐ichi¹²,Kitawaki Toshio¹^ORCID,Otsuka Yasuyuki¹,Takaori‐Kondo Akifumi¹,Kadowaki Norimitsu³

Affiliation:

1. Department of Hematology and Oncology Graduate School of Medicine Kyoto University Kyoto Japan

2. Department of Microbiology and Immunology University of California San Francisco San Francisco CA USA

3. Division of Hematology, Rheumatology and Respiratory Medicine Department of Internal Medicine Faculty of Medicine Kagawa University Kagawa Japan

Publisher

Wiley

Subject

Cancer Research,Oncology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/cas.14692

Reference31 articles.

1. Natural killer or natural killer/T cell lineage large granular lymphocytosis associated with dasatinib therapy for Philadelphia chromosome positive leukemia

2. Clonal expansion of T/NK-cells during tyrosine kinase inhibitor dasatinib therapy

3. Expansion of highly differentiated CD8+ T-cells or NK-cells in patients treated with dasatinib is associated with cytomegalovirus reactivation

4. Principal component analysis uncovers cytomegalovirus-associated NK cell activation in Ph+ leukemia patients treated with dasatinib

5. Discontinuation of dasatinib in patients with chronic myeloid leukaemia who have maintained deep molecular response for longer than 1 year (DADI trial): a multicentre phase 2 trial

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Early dose reduction of dasatinib does not compromise clinical outcomes in patients with chronic myeloid leukemia: A comparative analysis of two prospective trials;Leukemia Research;2024-08

2. NK92 cells and peripheral blood NK cells respond oppositely upon dasatinib treatment;Immunology;2024-02-15

3. The role of exhausted natural killer cells in the immunopathogenesis and treatment of leukemia;Cell Communication and Signaling;2024-01-22

4. Markers of Natural Killer Cell Exhaustion in HIV/HCV Coinfection and Their Dynamics After HCV Clearance Mediated by Direct-Acting Antivirals;Open Forum Infectious Diseases;2023-11-22

5. Progress of research on PD-1/PD-L1 in leukemia;Frontiers in Immunology;2023-09-26